RMC No. 72-2023 — Publishes the May 22, 2023 letter from the Food and Drug Administration of the DOH endorsing updates to the List of VAT-Exempt Medicines under RA No. 10963 (TRAIN Law) and RA No. 11534 (CREATE Act) Digest | Full Text | Annex A

REPUBLIC OF THE PHILIPPINES

BUREAU OF INTERNAL REVENUE DEPARTMENT OF FINANCE

JUN 2 0 2023

REVENUE MEMORANDUM CIRCULAR NO. 72- 2023

SUBJECT : Publishing the Full Text of the May 22,2023 Letter from the Food and Drug No. 10963 (TRAIN Law) and R.A. No. 11534 (CREATE Act) Administration (FDA) of the Department of Health (DOH) Endorsing Updates to the List of VAT-Exempt Products Under Republic Act (R.A.)

TO : All Internal Revenue Officers and Others Concerned

For the information and guidance of all internal revenue officers, employees and others concerned, attached is the May 22, 2023 letter (Annex "A") from Dr. Samuel A. Zacate,

Under R.A. No. 11534 or the CREATE Act, particularly the following: Director General of the FDA, for an update to the published List of VAT-Exempt Medicines

1. Inclusion of certain medicines for cancer, diabetes, high cholesterol, hypertension. kidney disease, mental illness, and tuberculosis; 2. Correction of medicine for hypertension; and 3. Deletion of medicine for cancer.

As clarified under Q&A No. 1 of RMC No. 99-2021, the effectivityof the VAT exemption of the covered medicines and medical devices under the CREATE Act shall be on the date of publication by the FDA of the updates to the said list.

wide a publicity as possible. All concerned are hereby enjoined to be guided accordingly and give this Circular as

GUI. JR tc Hissioner of Internal Revenue

010428

INTERNAL COMNUNICATIONS DIVISION JUREAU OF INTERNAL REVENUE JUN 29 BUREAU OF INTERNAL REVENUE JUN 2 9 20Z3L Ntiyr F&0 ArS

jCUJC1 y u Records Mgt division yg